Literature DB >> 22836708

Glomerular filtration rate estimated by Cockcroft-Gault formula better predicts anti-Xa levels than modification of the diet in renal disease equation in older patients with prophylactic enoxaparin.

B Dufour1, M Toussaint-Hacquard, A Kearney-Schwartz, M D P Manckoundia, M C Laurain, L Joly, J Deibener, D Wahl, T Lecompte, A Benetos, C Perret-Guillaume.   

Abstract

OBJECTIVES: Older people have an increased risk of low molecular weight heparin accumulation leading to an increased bleeding risk. The objective of this study was to assess whether reduced glomerular filtration rate (GFR), estimated by the Cockcroft-Gault or modification of the diet in renal disease (MDRD) equations, indicates drug accumulation by increased anti-Xa levels in older subjects receiving prophylactic enoxaparin treatment.
DESIGN: Cohort study.
SETTING: Acute geriatric units in Nancy Hospital. PARTICIPANTS: Ninety-two consenting consecutive patients, 65 and older, confined to bed for an acute medical condition requiring enoxaparin for prevention of venous thromboembolism, and hospitalized for at least six days were enrolled. MEASUREMENTS: Serum creatinine and peak plasma anti-Xa levels 3 to 4 hours after the daily injection of enoxaparin were measured at days 3, 6, 9 and 12 (first dose of enoxaparin at day one). Analyses of variance for repeated measures were used to evaluate significant predictors of peak anti-Xa activity in univariate and multivariate analyses.
RESULTS: A significant correlation was observed between anti-Xa activity and GFR estimated with the Cockcroft formula r=0.43. Following univariate analysis, the three factors associated with higher anti-Xa levels were a lower Cockcroft-Gault GFR (p=0.0002), female gender (p=0.0003) and a lower bodyweight (p<.0001). No significant association between anti-Xa levels and MDRD GFR (p=0.33) was observed. Following multivariate analysis, female gender (p=0.02), bodyweight (p=0.04) and Cockcroft GFR (p=0.05) remained independent determinants of anti-Xa levels.
CONCLUSION: In hospitalized patients older than 65 years old, the Cockcroft-Gault equation, in contrast to the MDRD equation, is able to predict the risk of higher anti-Xa levels.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22836708     DOI: 10.1007/s12603-012-0072-6

Source DB:  PubMed          Journal:  J Nutr Health Aging        ISSN: 1279-7707            Impact factor:   4.075


  28 in total

1.  Incidence of venous thromboembolism: a community-based study in Western France. EPI-GETBP Study Group. Groupe d'Etude de la Thrombose de Bretagne Occidentale.

Authors:  E Oger
Journal:  Thromb Haemost       Date:  2000-05       Impact factor: 5.249

2.  Efficacy and safety of fondaparinux for the prevention of venous thromboembolism in older acute medical patients: randomised placebo controlled trial.

Authors:  Alexander T Cohen; Bruce L Davidson; Alexander S Gallus; Michael R Lassen; Martin H Prins; Witold Tomkowski; Alexander G G Turpie; Jan F M Egberts; Anthonie W A Lensing
Journal:  BMJ       Date:  2006-01-26

3.  New oral antithrombotics: a need for laboratory monitoring. For.

Authors:  P Mismetti; S Laporte
Journal:  J Thromb Haemost       Date:  2010-01-21       Impact factor: 5.824

Review 4.  College of American Pathologists Conference XXXI on laboratory monitoring of anticoagulant therapy: the clinical use and laboratory monitoring of low-molecular-weight heparin, danaparoid, hirudin and related compounds, and argatroban.

Authors:  M Laposata; D Green; E M Van Cott; T W Barrowcliffe; S H Goodnight; R C Sosolik
Journal:  Arch Pathol Lab Med       Date:  1998-09       Impact factor: 5.534

5.  Occurrence of thrombosis and haemorrhage, relationship with anti-Xa, anti-IIa activities, and D-dimer plasma levels in patients receiving a low molecular weight heparin, enoxaparin or tinzaparin, to prevent deep vein thrombosis after hip surgery.

Authors:  L Bara; A Planes; M M Samama
Journal:  Br J Haematol       Date:  1999-02       Impact factor: 6.998

6.  A more accurate method to estimate glomerular filtration rate from serum creatinine: a new prediction equation. Modification of Diet in Renal Disease Study Group.

Authors:  A S Levey; J P Bosch; J B Lewis; T Greene; N Rogers; D Roth
Journal:  Ann Intern Med       Date:  1999-03-16       Impact factor: 25.391

7.  Correlation of plasma coagulation parameters with thromboprophylaxis, patient characteristics, and outcome in the MEDENOX study.

Authors:  Louis Desjardins; Lucienne Bara; Florent Boutitie; Meyer Michel Samama; Alexander T Cohen; Sophie Combe; Charles Janbon; Alain Leizorovicz; Carl-Gustav Olsson; Alexander G G Turpie
Journal:  Arch Pathol Lab Med       Date:  2004-05       Impact factor: 5.534

8.  Heparin and low-molecular-weight heparin: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy.

Authors:  Jack Hirsh; Robert Raschke
Journal:  Chest       Date:  2004-09       Impact factor: 9.410

9.  Aging and venous thromboembolism influence the pharmacodynamics of the anti-factor Xa and anti-thrombin activities of a low molecular weight heparin (nadroparin).

Authors:  P Mismetti; S Laporte-Simitsidis; C Navarro; P Sié; P d'Azemar; J Necciari; J P Duret; C Gaud; H Decousus; B Boneu
Journal:  Thromb Haemost       Date:  1998-06       Impact factor: 5.249

10.  Anti-factor Xa activity of enoxaparin administered at prophylactic dosage to patients over 75 years old.

Authors:  A Berges; S Laporte; M Epinat; P Zufferey; E Alamartine; B Tranchand; H Decousus; P Mismetti
Journal:  Br J Clin Pharmacol       Date:  2007-05-17       Impact factor: 4.335

View more
  4 in total

1.  Discrepancies between the Cockcroft-Gault and Chronic Kidney Disease Epidemiology (CKD-EPI) Equations: Implications for Refining Drug Dosage Adjustment Strategies.

Authors:  Pierre Delanaye; Fabrice Guerber; André Scheen; Timothy Ellam; Antoine Bouquegneau; Dorra Guergour; Christophe Mariat; Hans Pottel
Journal:  Clin Pharmacokinet       Date:  2017-02       Impact factor: 6.447

Review 2.  Optimizing the use of anticoagulants (heparins and oral anticoagulants) in the elderly.

Authors:  Virginie Siguret; Isabelle Gouin-Thibault; Pascale Gaussem; Eric Pautas
Journal:  Drugs Aging       Date:  2013-09       Impact factor: 3.923

3.  Treatment with Dalteparin is Associated with a Lower Risk of Bleeding Compared to Treatment with Unfractionated Heparin in Patients with Renal Insufficiency.

Authors:  Doyun Park; William Southern; Manuela Calvo; Margarita Kushnir; Clemencia Solorzano; Mark Sinnet; Henny H Billett
Journal:  J Gen Intern Med       Date:  2015-07-25       Impact factor: 5.128

4.  Creatinine-based equations for the adjustment of drug dosage in an obese population.

Authors:  Antoine Bouquegneau; Emmanuelle Vidal-Petiot; Olivier Moranne; Christophe Mariat; Jean-Jacques Boffa; François Vrtovsnik; André-Jean Scheen; Jean-Marie Krzesinski; Martin Flamant; Pierre Delanaye
Journal:  Br J Clin Pharmacol       Date:  2016-01-17       Impact factor: 4.335

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.